**Cost-Effectiveness of Brentuximab Vedotin for the Treatment of Cutaneous T-cell Lymphoma: Appendix**

Table A. Clinical Inputs.

|  |  |  |  |
| --- | --- | --- | --- |
| Parametric Curves | Input | Source | Scenario Analysis |
| OS |  |  |  |
| BV | Same as PC | Assumption | 1. OS benefit for BV:  a. 2-months  b. 4-months  c. 9.5-months |
| PC | Log-logistic | 1 | 2. Log-normal (PC) |
| alloSCT | Log-normal | 2 | 3. Weibull (alloSCT) |
| PFS |  |  |  |
| BV | Weibull | 1 | 4. Exponential (BV and PC) |
| PC | Weibull | 1 |
| alloSCT | Gompertz | 2 |  |
| Time on treatment |  |  |  |
| BV | Actual data | 1 |  |
| PC | Actual data | 1 |  |
| Time of treatment before alloSCT eligibility | 18 weeks\* (i.e. 6 cycles of BV) | Expert opinion | 5. Timing of alloSCT: a. 12-weeks  b. 24-weeks |
| Responders eligible for alloSCT | 40% | Expert opinion | 6. 20% of responders eligible for alloSCT |
| Subsequent therapy: Proportion treated |  | EU PROCLIPI data on file |  |
| Subsequent therapy: Time on treatment (weeks) |  |  |  |
| Gemcitabine | 16.0 | 3 |  |
| CHOP | 9.0 | Expert opinion |  |
| Other mono chemotherapy | 24.0 | 4 |  |
| TSEB | 47.8 | 5 |  |
| Background mortality | England and Wales’ life tables 2014–2016 | 6 |  |

Abbreviations: BEX, bexarotene; BV, brentuximab vedotin; CHOP, cyclophosphamide, doxorubicin, vincristine, prednisone; MTX, methotrexate; OS, overall survival; PC, physician’s choice; PFS, progression-free survival; TSEB, total skin electron beam therapy.

\*Expert opinion provided the number of cycles, which was translated into weeks

Table A. Cost Inputs.

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Cost category | Unit cost | Cycle cost | Source | Scenario Analysis |
| Drug costs |  |  |  |  |
| BV | £2,500.00 | £2,500.00 | MIMS 7 |  |
| MTX | £1.44 | £0.51 | MIMS 8 |  |
| BEX | £937.50 | £459.38 | MIMS 9 |  |
| alloSCT | £96,956 | -- | 10 | 7. £65,154 (NHS Reference costs) |
| Subsequent therapy |  |  |  |  |
| Gemcitabine | 200 mg: £30.93  1000 mg: £154.62  2000 mg: £324.00 | £694.76 | Unit costs: MIMS 11  Dosing: LCA SACT 12 |  |
| CHOP | -- | £97.54 | Unit costs: MIMS 13-16  Dosing: LCA SACT 17 |  |
| Cyclophosphamide | 50 mg: £139.00 | £13.44 |  |
| Hydroxydaunorubicin | 10 ml: £18.54  50 ml: £92.70  200 ml: £391.40 | £61.80 |  |
| Oncovin (vincristine) | 1 ml: £67.35  2 ml: £133.30  5 ml: £329.50 | £13.38 |  |
| Prednisolone | 1 mg: £0.37  5 mg: £0.47  25 mg: £75.00 | £8.93 |  |
| Other mono chemotherapy\* | -- | £151.29 | Unit costs: MIMS18  Dosing: LCA SACT |  |
| TSEB | -- | £72.67 | Unit costs: NHS Reference Costs 19  Dosing: Guys Hospital |  |
| Administration costs |  |  |  |  |
| BV | -- | £58.00 | 19,20 |  |
| MTX | -- | £0 | Assumption |  |
| BEX | -- | £0 | Assumption |  |
| Gemcitabine | -- | £130.49 | 19,20 |  |
| CHOP | -- | £173.99 | LCA SCAT 17 |  |
| Other mono chemotherapy\* | -- | £164.64 | LCA SCAT 21 |  |
| Adverse event costs |  |  |  |  |
| BV | -- | £4.97 | 19 |  |
| PC | -- | £5.99 | 19 |  |
| Resource use costs |  |  |  | 8. See Table A3 |
| Pre-progression | -- | £388.63 | Expert opinion |  |
| Post-progression | -- | £904.45 | Expert opinion |  |
| End-stage care (specific to advanced CTCL) | -- | £2,094.92 | Expert opinion |  |
| End-stage care (generic oncology disease) | -- | £286.48 | 22 |  |
| Indirect costs |  |  |  |  |
| Pre-progression | -- | £62.72 | Average number of hospital visits/week: assumption  Costs: 23-26 |  |
| Post-progression | -- | £199.76 |  |
| End-stage care | -- | £288.02 |  |

Abbreviations: BEX, bexarotene; BV, brentuximab vedotin; LCA, London Cancer Alliance; MTX, methotrexate; PAS, patient access scheme; SACT, systemic anti-cancer therapy.

Notes: \*Other mono chemotherapy includes doxorubicin (all formulations) and chlorambucil.

**Additional details on drug costs and administration costs**

Model costs for each drug were estimated based on weight or body surface area as follows:

* The cycle cost of BV is estimated based on a dose of 1.8 mg/kg during a 21-day treatment cycle with a relative dose intensity of 95%.1,27
* The cycle cost of MTX is estimated based on a dose of 23.44 mg during a 7-day treatment cycle. 1,27
* The cycle cost of BEX is estimated based on a dose of 300 mg/m2 during a 1-day treatment cycle with a relative dose intensity of 90%.1,27
* The cycle cost of gemcitabine is estimated based on a dose of 3000 mg/m2 during a 28-day treatment cycle.12
* The cycle cost of CHOP is estimated based on the dose of the component therapies (Cyclophosphamide: 750 mg/m2; Hydroxydaunorubicin: 50 mg/m2; Oncovin (vincristine): 1.4 mg/m2; Prednisolone: 100 mg) during a 21-day treatment cycle.17
* The cost of 2 weeks on TSEB therapy is spread over the average duration of response of 11 months.

Administration unit costs are estimated from NHS reference costs 2016/17. All IV therapies, including BV, are costed as simple therapies with the exceptions of doxorubicin (costed as complex chemotherapy), and CHOP, for which each of the three IV therapies is costed as simple chemotherapy, with no cost assumed for prednisolone. For oral therapies, the administrative cost for chlorambucil includes costs for oral dispensing; however, the oral dispensing cost is not included for MTX or BEX.

Table A3: Resource utilization.

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | Base case | | Scenario Analysis: 9. Lower-range resource utilization | |
|  | **% Patients** | **Frequency per week** | **% Patients** | **Frequency per week** |
| End-stage care |  |  |  |  |
| Hospital outpatient |  |  |  |  |
| Clinical nurse specialist | 100 | 2.25 | 100 | 1.63 |
| Dermatologist visit | 100 | 0.17 | 100 | 0.17 |
| Psychologist | 50 | 0.25 | 5 | 0.25 |
| Home visit |  |  |  |  |
| District nurse visit | 100 | 2.63 | 100 | 2.63 |
| Macmillan nurse/social services | 100 | 1 | 100 | 0.5 |
| Palliative care support team | 100 | 2 | 100 | 0.5 |
| Dressings |  |  |  |  |
| Meptiel dressings | 25 | 7 (x3) | 12.5 | 7 (x3) |
| Mepilex large sheet dressings | 25 | 7 (x2) | 12.5 | 7 (x2) |
| Mepilex heels | 25 | 7 (x2) | 12.5 | 7 (x2) |
| Elasticated garments | 25 | 1 (x3) | 12.5 | 1 (x3) |
| Medium Allevyn | 75 | 7 | 75 | 7 |
| Pre-progression / Post -progression |  |  |  |  |
| District nurse visit | 100 | 2.6 | 100 | 0.25 |
| Dressings - localised coverage | 60 | 7 (x7) | 37.5 | 7 (x7) |

Table A4. Utility inputs.

|  |  |  |  |
| --- | --- | --- | --- |
| Health State | Utility | Source | Scenario Analysis |
| Progression free |  |  | Scenario 9: Predicted utilities27 |
| BV | 0.69 | Averaged observed utilities for BV and PC 27 | 0.68 |
| PC | 0.69 | 0.64 |
| Progressive disease | 0.64 | 0.61 |
| End stage care | 0.38 | 28 |  |
| alloSCT: 0-14 days | 0.42 | 29 |  |
| alloSCT: 14 days -3 months | 0.60 | 29 |  |
| alloSCT: >3 months | 0.77 | 29 |  |
|  |  |  |  |
| Adverse Event | **Disutility** | **Source** | Scenario 10: Disutilities from literature |
| Blood and lymphatic system disorders | 0 | Assumption | -0.10 30 |
| Gastrointestinal disorders | 0 | Assumption | -0.10 31 |
| General disorders and administration site conditions | 0 | Assumption | -0.07 32 |
| Multiorgan failure | 0 | Assumption | -0.20 30 |
| Infections and infestations | 0 | Assumption | -0.14 33 |
| Septicemia | 0 | Assumption | -0.20 30 |
| Peripheral neuropathy | 0 | Assumption | -0.11 28 |
| Skin and subcutaneous tissue disorders | 0 | Assumption | -0.03 32 |
| Investigations | 0 | Assumption |  |
| Hypertriglyceridemia | 0 | Assumption |  |

Abbreviations: alloSCT, allogenic stem cell transplant; BV, brentuximab vedotin; PC, physician’s choice.

**References:**

1. Horwitz SM, Scarisbrick JJ, Dummer R, et al: Updated Analyses of the International, Open-Label, Randomized, Phase 3 Alcanza Study: Longer-Term Evidence for Superiority of Brentuximab Vedotin Versus Methotrexate or Bexarotene for CD30-Positive Cutaneous T-Cell Lymphoma (CTCL), Am Soc Hematology, 2017

2. Palanicawandar R, Morris S, Lozano-Cerrada S, et al: Allogeneic Stem Cell Transplantation for Advanced Cutaneous T-Cell Lymphoma with Minimal-Intensity Conditioning, European Organisation for Research and Treatment of Cancer, 2017

3. Duvic M, Tetzlaff MT, Gangar P, et al: Results of a Phase II Trial of Brentuximab Vedotin for CD30+ Cutaneous T-Cell Lymphoma and Lymphomatoid Papulosis. J Clin Oncol 33:3759-65, 2015

4. Dummer R, Quaglino P, Becker JC, et al: Prospective international multicenter phase II trial of intravenous pegylated liposomal doxorubicin monochemotherapy in patients with stage IIB, IVA, or IVB advanced mycosis fungoides: final results from EORTC 21012. J Clin Oncol 30:4091-7, 2012

5. Morris S, Scarisbrick J, Frew J, et al: The Results of Low-Dose Total Skin Electron Beam Radiation Therapy (TSEB) in Patients With Mycosis Fungoides From the UK Cutaneous Lymphoma Group. Int J Radiat Oncol Biol Phys 99:627-633, 2017

6. Office for National Statistics: National life tables, UK: 2014 to 2016. Statistical bulletin, 2017

7. Monthly Index of Medical Specialities (MIMS): Brentuximab vedotin - Adcetris, 2018

8. Monthly Index of Medical Specialities (MIMS): Methotrexate, 2018

9. Monthly Index of Medical Specialities (MIMS): Bexarotene - Targretin, 2018

10. Debals-Gonthier M, Siani C, Faucher C, et al: Cost-effectiveness analysis of haploidentical vs matched unrelated allogeneic hematopoietic stem cells transplantation in patients older than 55 years. Bone Marrow Transplantation, 2018

11. Monthly Index of Medical Specialities (MIMS): Gemcitabine, 2018

12. London Cancer Alliance: LCA skin SACT protocols - non melanoma - Gemcitabine, 2015

13. Monthly Index of Medical Specialities (MIMS): Cyclophosphamide, 2018

14. Monthly Index of Medical Specialities (MIMS): Doxorubicin hydrochlor - Doxorubicin, 2018

15. Monthly Index of Medical Specialities (MIMS): Oncovin - Vincristine (Vincristine sulf.) 2018

16. Monthly Index of Medical Specialities (MIMS): Prednisolone, 2018

17. London Cancer Alliance: LCA skin SACT protocols - non melanoma - CHOP +/- Rituximab, 2015

18. Monthly Index of Medical Specialities (MIMS): Caelyx - Doxorubicin hydrochlor in pegylated liposomes, 2018

19. National Health Service (NHS): NHS reference costs 2015 to 2016, in Health Do (ed). London, UK, 2016

20. Department of Health: Reference costs guidance 2015-16, 2016

21. London Cancer Alliance: LCA skin SACT protocols - non melanoma - Pegylated Liposomal Doxorubicin (Caelyx), 2015

22. Round J, Jones L, Morris S: Estimating the cost of caring for people with cancer at the end of life: A modelling study. Palliat Med 29:899-907, 2015

23. Office for National Statistics (ONS): EARN01: Average Weekly Earnings. 2018. ,

24. Macmillan: The hidden cost of hospital car parking, 2013

25. The AA: Motoring Costs 2014, 2014

26. Roberts A, Blunt I, Bardsley M: Focus On: Distance from home to emergency care, Evidence for better health care: Nuffield Trust, 2014

27. Prince HM, Kim YH, Horwitz SM, et al: Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial. Lancet 390:555-566, 2017

28. Swinburn P, Shingler S, Acaster S, et al: Health utilities in relation to treatment response and adverse events in relapsed/refractory Hodgkin lymphoma and systemic anaplastic large cell lymphoma. Leukemia & Lymphoma 56:1839-1845, 2015

29. van Agthoven M, Vellenga E, Fibbe WE, et al: Cost analysis and quality of life assessment comparing patients undergoing autologous peripheral blood stem cell transplantation or autologous bone marrow transplantation for refractory or relapsed non-Hodgkin's lymphoma or Hodgkin's disease: a prospective randomised trial. European Journal of Cancer 37:1781-1789, 2001

30. Beusterien KM, Davies J, Leach M, et al: Population preference values for treatment outcomes in chronic lymphocytic leukaemia: a cross-sectional utility study. Health Qual Life Outcomes 8:50, 2010


31. Lloyd A, Nafees B, Narewska J, et al: Health state utilities for metastatic breast cancer. Br J Cancer 95:683-90, 2006

32. Nafees B, Stafford M, Gavriel S, et al: Health state utilities for non small cell lung cancer. Health Qual Life Outcomes 6:84, 2008

33. Brown RE, Hutton J, Burrell A: Cost effectiveness of treatment options in advanced breast cancer in the UK. Pharmacoeconomics 19:1091-102, 2001

**Figures**

Figure A. Probabilistic sensitivity analysis scatterplot.



Abbreviations: QALY, quality adjusted life year.